Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant [0.03%]
一日一次 extended-release 西罗莫司片剂与一日二次软胶囊在肝移植中的药代动力学研究
Derek A DuBay,Lewis Teperman,Kimi Ueda et al.
Derek A DuBay et al.
The pharmacokinetics of once-daily extended-release tacrolimus tablets (LCPT) in de novo liver transplantation have not been previously reported. In this phase II, randomized, open-label study, de novo liver transplant recipients were rando...
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers [0.03%]
ELX-02的安全性，耐受性和药代动力学：在健康志愿者中的单次递增剂量给药试验，有望用于 nonsense mutations遗传病的治疗
Andi Leubitz,Anat Frydman-Marom,Neal Sharpe et al.
Andi Leubitz et al.
ELX-02 is an investigational synthetic eukaryotic ribosome-selective glycoside optimized as a translational read-through molecule that induces read through of nonsense mutations, resulting in normally localized full-length functional protei...
A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics [0.03%]
一项在健康成人受试者中评价普拉莫西林对心电图QT/QTc间期影响、安全性和药代动力学的I期临床试验
Jonathan Gall,Taylor Choi,Valerie Riddle et al.
Jonathan Gall et al.
Plazomicin is an aminoglycoside with in vitro activity against multidrug-resistant Enterobacteriaceae. A phase 1, randomized, double-blind, crossover study assessed the potential effects of plazomicin on cardiac repolarization (NCT01514929)...
A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet [0.03%]
依 Zu 特若米德在杜氏肌营养不良平衡饮食的儿科患者中的药代动力学：Ib 期试验
Francesco Muntoni,Bina Tejura,Stefan Spinty et al.
Francesco Muntoni et al.
Ezutromid (SMT C1100) is a small-molecule utrophin modulator that was developed to treat Duchenne muscular dystrophy (DMD). Previous clinical trials of this agent revealed lower exposure in DMD patients compared with healthy volunteers, whi...
A Phase 1 Randomized, Placebo-Controlled Trial With a Topical Inhibitor of Stearoyl-Coenzyme A Desaturase 1 Under Occluded and Nonoccluded Conditions [0.03%]
局部施用SCD1抑制剂的封包与非封包条件下的I期随机双盲安慰剂对照试验
Richard A Brigandi,John Zhu,Amy A Murnane et al.
Richard A Brigandi et al.
Stearoyl-coenzyme A desaturase 1 (SCD-1) in sebaceous glands is a key enzyme in the synthesis of monounsaturated fatty acids essential for acne development. GSK1940029 gel, a novel SCD-1 inhibitor, is being developed as a potential treatmen...
Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects [0.03%]
阿塔卢林在健康日本成人和白人成人中的药代动力学
Ronald Kong,Oscar L Laskin,Diksha Kaushik et al.
Ronald Kong et al.
To evaluate the potential for ethnicity-related differences in ataluren pharmacokinetics (PK) and safety, a phase 1 single-dose study was conducted in 48 healthy (24 Japanese and 24 Caucasian subjects), nonsmoking male volunteers who were e...
Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects [0.03%]
用于HCV感染者的达克拉韦/阿舒纳普韦/贝卡芦布韦联合方案的群体药代动力学分析
Mayu Osawa,Takayo Ueno,Tomomi Shiozaki et al.
Mayu Osawa et al.
A fixed-dose combination of daclatasvir (pangenotypic NS5A inhibitor), asunaprevir (NS3/4A protease inhibitor), and beclabuvir (nonnucleoside NS5B inhibitor) was approved for hepatitis C virus treatment in Japan. The objectives of the analy...
An Open-Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant [0.03%]
口服罗拉匹坦开放标签、随机对照生物等效性关键性研究
Zhi-Yi Zhang,Jing Wang,Sujata Arora et al.
Zhi-Yi Zhang et al.
Rolapitant, a selective and long-acting neurokinin-1 receptor antagonist, is approved in an oral formulation for prevention of delayed chemotherapy-induced nausea and vomiting in adults. This pivotal open-label, randomized, single-dose, mul...
Randomized Controlled Trial
Clinical pharmacology in drug development. 2019 Feb;8(2):152-159. DOI:10.1002/cpdd.651 2019
No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects [0.03%]
普拉莫西林对受试者体内二甲双胍药代动力学无影响
Taylor Choi,Allison S Komirenko,Valerie Riddle et al.
Taylor Choi et al.
Plazomicin is an aminoglycoside that was engineered to overcome aminoglycoside-modifying enzymes, which are the most common aminoglycoside resistance mechanism in Enterobacteriaceae. Because plazomicin is predominantly eliminated via renal ...
David J Greenblatt,Gerd Mikus
David J Greenblatt